Laboratory assessment of antiphospholipid syndrome: Laboratory data.
antiphospholipid antibodies
antiphospholipid syndrome
blood coagulation disorders
clinical practice pattern
lupus anticoagulant
Journal
International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
received:
04
10
2023
accepted:
07
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
2
4
2024
Statut:
aheadofprint
Résumé
Thorough assessment of the antiphospholipid syndrome (APS) includes retesting of positive antiphospholipid antibody (aPL) tests after at least 12 weeks, and a full antiphospholipid antibody profile. To what extent this work-up is done in clinical practice is unknown. Data on 25 116 in- and out-hospital patients tested for the presence of lupus anticoagulant (LA), the aPL which most strongly correlates with thrombosis, was extracted from the laboratory information system of the only laboratory that performs LA tests in the Capital Region, Denmark. We estimated fraction of repeated tests, tests repeated within the recommended time span, and fraction with a full aPL profile. Out of 25 116 patients, 843 were positive for LA (3.3%), and 3948 results were inconclusive (16%). Only 51% (95% CI of the proportion: 48%-54%) (n = 431) of positive tests were repeated. The proportion of inconclusive LA test results increased from 13% (12%-15%) in 2009 to 20% (19%-22%) in 2020. Out of the positive tests repeated within the first year, only 60/353 (17%; 13%-21%) were repeated within 12-16 weeks; 177/353 (50%; 45%-55%) were re-tested within the first 12 weeks of first positive test result. The proportion of patients with a full antiphospholipid antibody profile increased from 161/1978 (8%) in 2010 to 1041/1978 (43%) in 2020. We found several issues with the laboratory workup of APS. This indicates a need for increased awareness of comprehensive laboratory assessment of possible APS as well as a closer collaboration between the laboratory and clinicians.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Clinical Biochemistry, Rigshospitalet and Department of Clinical Biochemistry, Herlev-Gentofte Hospital
Informations de copyright
© 2024 The Authors. International Journal of Laboratory Hematology published by John Wiley & Sons Ltd.
Références
Yao K, Zhang L, Zhou H, Tang N, Li D. Plasma antiphospholipid antibodies effects on activated partial thromboplastin time assays. Am J Med Sci. 2017;354:22‐26.
Galli M. Antiphospholipid syndrome: association between laboratory tests and clinical practice. Pathophysiol Haemost Thromb. 2004;2003(33):249‐255.
Galli M, Luciani D, Bertolini G, Barbui T. Anti‐beta 2‐glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;15(102):2717‐2723.
Reber G, de Moerloose P. Anti‐β2‐glycoprotein I antibodies—when and how should they be measured? Thromb Res. 2004;114:527‐531.
Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023;75:1687‐1702.
Favaloro EJ, Pasalic L, Lippi G. Classification criteria for the antiphospholipid syndrome: not the same as diagnostic criteria for antiphospholipid syndrome. Semin Thromb Hemost. 2023. Online ahead of print. doi:10.1055/s‐0043‐1776318
Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309‐1311.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295‐306.
Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18:2828‐2839.
Cohen H, Mackie IJ, Devreese KMJ, International Society for T, Haemostasis S. Standardization Committee for Lupus anticoagulant/antiphospholipid a. clinical and laboratory practice for lupus anticoagulant testing: an International Society of Thrombosis and Haemostasis Scientific and standardization committee survey. J Thromb Haemost. 2019;17:1715‐1732.
Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high‐risk patients with antiphospholipid syndrome. Blood. 2018;132:1365‐1371.
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296‐1304.
Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the scientific and standardization Committee of the International Society on thrombosis and Haemostasis. J Thromb Haemost. 2020;18:2126‐2137.
Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation Committee of the International Society on thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737‐1740.
Favaloro EJ, Mohammed S, Vong R, et al. A multi‐laboratory assessment of lupus anticoagulant assays performed on the ACL TOP 50 family for harmonized testing in a large laboratory network. Int J Lab Hematol. 2022;44:654‐665.
Vivero A, Kitahara S, Runge A, Volod O. Consultative interpretation for lupus anticoagulant by expert pathologist reduces false‐positive rates in the era of direct Oral anticoagulants. J Appl Lab Med. 2020;5:73‐82.
Clark CA, Davidovits J, Spitzer KA, Laskin CA. The lupus anticoagulant: results from 2257 patients attending a high‐risk pregnancy clinic. Blood. 2013;122:341‐347. quiz 466.
Sugiura‐Ogasawara M, Atsumi T, Yamada H, et al. Real‐world practice of obstetricians in respect of assays for antiphospholipid antibodies. Mod Rheumatol. 2015;25:883‐887.
Kwon AJ, Roshal M, DeSancho MT. Clinical adherence to thrombophilia screening guidelines at a major tertiary care hospital. J Thromb Haemost. 2016;14:982‐986.
Devignes J, Smail‐Tabbone M, Herve A, et al. Extended persistence of antiphospholipid antibodies beyond the 12‐week time interval: association with baseline antiphospholipid antibodies titres. Int J Lab Hematol. 2019;41:726‐730.
Egiziano G, Widdifield J, Rahman A, et al. Antiphospholipid antibody testing in a general population sample from the USA: an administrative database study. Sci Rep. 2020;10:3102.
Sindet‐Pedersen C, Pallisgaard JL, Staerk L, et al. Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism: a Danish nationwide cohort study. Sci Rep. 2017;7:3347.
Flieder T, Weiser M, Eller T, et al. Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants. Thromb Res. 2018;165:101‐106.
Aljabry MS. Current practices for lupus anticoagulant testing at a tertiary care hospital and impact on laboratory resources. Ann Saudi Med. 2015;35:383‐386.
Mou E, Kwang H, Hom J, et al. Magnitude of potentially inappropriate thrombophilia testing in the inpatient hospital setting. J Hosp Med. 2017;12:735‐738.
De Kesel PM, Devreese KMJ. Direct oral anticoagulant adsorption: impact on lupus anticoagulant testing‐review of the literature and evaluation on spiked and patient samples. J Thromb Haemost. 2020;18:2003‐2017.
Moore GW, Jones PO, Platton S, et al. International multicenter, multiplatform study to validate taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC subcommittee on lupus anticoagulant/antiphospholipid antibodies. J Thromb Haemost. 2021;19:3177‐3192.
Sanmarco M, Soler C, Christides C, et al. Prevalence and clinical significance of IgG isotype anti‐beta 2‐glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med. 1997;129:499‐506.
Cox N, Johnson SA, Vazquez S, et al. Patterns and appropriateness of thrombophilia testing in an Academic Medical Center. J Hosp Med. 2017;12:705‐709.
Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010;9:A299‐A304.
Vollmer O, Tacquard C, Dieudonne Y, et al. Follow‐up of COVID‐19 patients: LA is transient but other aPLs are persistent. Autoimmun Rev. 2021;20:102822.
Favaloro EJ, Reben R, Mohammed S, Koutts J. Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations. Intern Med J. 2012;42:427‐434.
Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case‐control study. Lancet Neurol. 2009;8:998‐1005.
Dabit JY, Valenzuela‐Almada MO, Vallejo‐Ramos S, Duarte‐Garcia A. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep. 2022;23:85.
Goldman‐Mazur S, Wypasek E, Karpinski M, Stanisz A, Undas A. High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening. Thromb Res. 2019;176:67‐73.
Juul K, Tybjaerg‐Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City heart study and 2 meta‐analyses. Blood. 2002;100:3‐10.